XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.25.3

Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders | 9 Months Ended
--- | ---
Sep. 28, 2025
Earnings Per Share [Abstract] |
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders | Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders
The following presents the detailed calculation of EPS:
|  | Three Months Ended |  | Nine Months Ended
(MILLIONS) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024
EPS Numerator |  |  |  |  |  |  |  |
Income from continuing operations attributable to Pfizer Inc. common shareholders |  | $ | 3,541 |  |  | $ | 4,473 |  |  | $ | 9,393 |  |  | $ | 7,617 |
Discontinued operations––net of tax |  | — |  |  | (8) |  |  | 25 |  |  | 4 |
Net income attributable to Pfizer Inc. common shareholders |  | $ | 3,541 |  |  | $ | 4,465 |  |  | $ | 9,419 |  |  | $ | 7,621 |
EPS Denominator |  |  |  |  |  |  |  |
Weighted-average number of common shares outstanding––Basic |  | 5,685 |  |  | 5,667 |  |  | 5,682 |  |  | 5,663 |
Common-share equivalents |  | 29 |  |  | 39 |  |  | 29 |  |  | 36 |
Weighted-average number of common shares outstanding––Diluted |  | 5,714 |  |  | 5,705 |  |  | 5,710 |  |  | 5,699 |
Anti-dilutive common stock equivalents(a) |  | 8 |  |  | 25 |  |  | 11 |  |  | 25 |
(a)These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration